The Investment Column: Carpetright chief can ride out the retail slowdown

Arm Holdings; CeNes Pharma


Our view: Tempting buy

Share price: 782p (-39.5p)

Phil Harris has witnessed more ups and downs in the marketplace than most retailers. So the head of the Carpetright chain is well-placed to judge the likely impact on his company of the present slowdown. The chances are he is getting ready for some rough weather.

Shares in the group he founded, then floated, and then attempted to take private again last year, fell sharply after sales in its UK and Ireland stores fell by a hefty 4 per cent in the third quarter to 26 January. This was worse than analysts had feared, and is an acceleration of the decline seen during the first half.

The picture was brighter elsewhere in the 650-strong chain. Sales were up 3.1 per cent in Belgium and Holland and 16 per cent in Poland, although it only has 10 stores.

Trading has been erratic – up in November, flat in December, and sharply down in the opening half of January. In recent weeks it picked up again.

A new distribution and carpet-cutting centre will open in April, but any gains from the expected improvements in efficiency will not show through until next year.

Lord Harris says the current year will finish in line with expectations, around £61.6m, but this will owe much to improvements driven by cost controls. Analysts seem certain to trim forecasts for 2009. Few anticipate anything other than marginal underlying growth.

Wobbly credit markets pulled the rug from under Lord Harris's attempt to take the group private late last year. He was offering 1250p, which now looks extraordinarily generous, considering the weakness in the market, which must have been apparent to such an experienced retailer. The price has fallen 37 per cent since tabling the offer.

If any trader is capable of riding out an economic storm, it is Lord Harris. On that basis, the shares, at just 12.3 times expected earnings, look tempting.

Arm Holdings

Our view: Hold

Share price: 94.25p (-23.75p)

Arm Holdings, the microchip designer and former dot.com star, was punished yesterday for a weaker-than-expected fourth quarter performance that strengthened the market's conviction that this year will be very tough. The company lost 20 per cent of its value, making it the heaviest faller in the FTSE 250.

Arm designs chips that power devices such as iPods, mobile phones, video game consoles, personal computers, cameras and set-top boxes – all products vulnerable to a consumer squeeze.

Arm collects royalties whenever a gadget containing one of its chips is sold by the likes of Sony, Ericsson and Toshiba. Since 1990 over 10 billion Arm microprocessors have been shipped to such heavyweight customers. The company has a strong order book, fuelled by the use of its technology in a growing number of digital devices. Its growth continues to outpace its competitors. There is no indication that customers are cancelling orders, but Arm is adopting a cautious approach to prospects, which, coupled with disappointing earnings, led to a sharp sell-off in the shares.

Final-quarter earnings fell from £11.5m to £9.4m, while revenue was 5 per cent lower at £64.3m, below forecasts, partly due to the weakening of the dollar against sterling.

Arm's intellectual property division, formerly known as Artisan, saw revenues fall as it restructured itself. The business designs components which go into computer chips.

For the year as a whole Arm produced revenue of £259m, up by 6 per cent, while profits grew 15 per cent to £86.7m. The company is guiding the market towards a similar sales rise this year, but over a longer three- to seven-year term expects a return to mid-teen growth which characterised its time as a stock market favourite.

Once worth £9bn, it has shrunk to £1bn. The shares sell on 17.5 times forecast earnings. Hold.

CeNes Pharma

Our view: Sit tight

Share price: 52.5p (+20.5p)

The biotech tiddler CeNes Pharmaceuticals leapt on a bid approach yesterday.

The company has been developing a painkiller, M6G, which is about to enter trials in the US. The drug has fewer side-effects than morphine, so there could be strong demand if it is successful. But for some time CeNes has been looking for a partner to help fund the cost of those trials. It wants an up-front payment, along with future royalties. So far no one has come forward, and before yesterday's rise, the shares had fallen 80 per cent since last year.

The market has been losing patience with biotechs. They emerged in the mid-1990s hovering up millions of pounds of investors' money in the quest for miracle drugs. Few have been successful. Institutions have banged a few heads together and forced the merger of some players.

The 62 per cent jump in the price values CeNes at £11.3m. A big pharma willing to take a punt on M6G may have decided to buy the whole company rather than pay to enter into a partnership venture to develop one of its lead products.

Investors should sit tight.

Start your day with The Independent, sign up for daily news emails
Voices
There will be a chance to bid for a rare example of the SAS Diary, collated by a former member of the regiment in the aftermath of World War II but only published – in a limited run of just 5,000 – in 2011
charity appealTime is running out to secure your favourite lot as our auction closes at 2pm tomorrow
Arts and Entertainment
Mark Wright has won The Apprentice 2014
tvThe Apprentice 2014 final
News
File: James Woods attends the 52nd New York Film Festival at Walter Reade Theater on September 27, 2014
peopleActor was tweeting in wake of NYPD police shooting
Arts and Entertainment
X Factor winner Ben Haenow has scored his first Christmas number one
music
PROMOTED VIDEO
ebooks
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Carlton Senior Appointments: Private Banking Manager - Intl Bank - Los Angeles

$200 - $350 per annum: Carlton Senior Appointments: Managing Producer – Office...

Carlton Senior Appointments: San Fran - Investment Advisor – Ind Advisory Firm

$125 - $225 per annum: Carlton Senior Appointments: San Fran - Investment Advi...

Sheridan Maine: Commercial Finance Manager

Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Sheridan Maine: Regulatory Reporting Accountant

Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Day In a Page

The week Hollywood got scared and had to grow up a bit

The week Hollywood got scared and had to grow up a bit

Sony suffered a chorus of disapproval after it withdrew 'The Interview', but it's not too late for it to take a stand, says Joan Smith
From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?

Panto dames: before and after

From Widow Twankey to Mother Goose, how do the men who play panto dames get themselves ready for the performance of a lifetime?
Thirties murder mystery novel is surprise runaway Christmas hit

Thirties murder mystery novel is surprise runaway Christmas hit

Booksellers say readers are turning away from dark modern thrillers and back to the golden age of crime writing
Anne-Marie Huby: 'Charities deserve the best,' says founder of JustGiving

Anne-Marie Huby: 'Charities deserve the best'

Ten million of us have used the JustGiving website to donate to good causes. Its co-founder says that being dynamic is as important as being kind
The botanist who hunts for giant trees at Kew Gardens

The man who hunts giants

A Kew Gardens botanist has found 25 new large tree species - and he's sure there are more out there
The 12 ways of Christmas: Spare a thought for those who will be working to keep others safe during the festive season

The 12 ways of Christmas

We speak to a dozen people who will be working to keep others safe, happy and healthy over the holidays
Birdwatching men have a lot in common with their feathered friends, new study shows

The male exhibits strange behaviour

A new study shows that birdwatching men have a lot in common with their feathered friends...
Diaries of Evelyn Waugh, Virginia Woolf and Noël Coward reveal how they coped with the December blues

Famous diaries: Christmas week in history

Noël Coward parties into the night, Alan Clark bemoans the cost of servants, Evelyn Waugh ponders his drinking…
From noble to narky, the fall of the open letter

From noble to narky, the fall of the open letter

The great tradition of St Paul and Zola reached its nadir with a hungry worker's rant to Russell Brand, says DJ Taylor
A Christmas ghost story by Alison Moore: A prodigal daughter has a breakthrough

A Christmas ghost story by Alison Moore

The story was published earlier this month in 'Poor Souls' Light: Seven Curious Tales'
Marian Keyes: The author on her pre-approved Christmas, true love's parking implications and living in the moment

Marian Keyes

The author on her pre-approved Christmas, true love's parking implications and living in the moment
Bill Granger recipes: Our chef creates an Italian-inspired fish feast for Christmas Eve

Bill Granger's Christmas Eve fish feast

Bill's Italian friends introduced him to the Roman Catholic custom of a lavish fish supper on Christmas Eve. Here, he gives the tradition his own spin…
Liverpool vs Arsenal: Brendan Rodgers is fighting for his reputation

Rodgers fights for his reputation

Liverpool manager tries to stay on his feet despite waves of criticism
Amir Khan: 'The Taliban can threaten me but I must speak out... innocent kids, killed over nothing. It’s sick in the mind'

Amir Khan attacks the Taliban

'They can threaten me but I must speak out... innocent kids, killed over nothing. It’s sick in the mind'
Michael Calvin: Sepp Blatter is my man of the year in sport. Bring on 2015, quick

Michael Calvin's Last Word

Sepp Blatter is my man of the year in sport. Bring on 2015, quick